Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib + Riluzole in ALS
NCT03127267Phase 3Recruiting
- Sponsor
- AB Science
- Start
- Feb 2021
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of masitinib in amyotrophic lateral sclerosis (ALS) (3 arms), sponsored by AB Science. Primary endpoint: ALS Functional Rating Scale-Revised at 48 weeks. Started Feb 2021; status: recruiting.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT03127267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03127267.